Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acadia Pharmaceuticals, Inc.
Pharmaceutical company expands technology platform
June 15th, 2005
Acadia Pharmaceuticals, Inc., (ACAD) reported on the development of assay technologies for a major class of drug targets, tyrosine kinase linked receptors (RTKs). This important gene family has been demonstrated to play a significant role in the development of many disease states, including central nervous system (CNS) disorders and cancer. In a poster presentation at the Molecular Pharmacology Gordon Conference in Il Ciocco, Italy, May 8-13, Acadia highlighted a novel application of BRET (Bioluminescence Resonance Energy Transfer) technology used to measure the interaction of RTKs with several signaling proteins. This assay...
Source: Physician Law Weekly (2005-06-15)
|
